{"product_id":"vesugen","title":"Vesugen","description":"\u003ch3\u003eVesugen (KED, Lys-Glu-Asp)\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eFull Research Introduction \u0026amp; Administration Guide \u003c\/span\u003e\u003cstrong\u003eIMPORTANT DISCLAIMER: For laboratory research use only. Not approved for human injection, clinical treatment or consumption. All dosing information is summarized from published preclinical literature purely for experimental reference.\u003c\/strong\u003e\u003cspan\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e1. Basic Overview\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eVesugen (Code T-38, Sequence \u003c\/span\u003e\u003cstrong\u003eLys-Glu-Asp \/ KED\u003c\/strong\u003e\u003cspan\u003e) is a synthetic short tripeptide bioregulator developed by the St. Petersburg Institute of Bioregulation and Gerontology (Khavinson peptide series). It is engineered to regulate vascular endothelial cell function.\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCAS Number: 204271-66-9\u003c\/li\u003e\n\u003cli\u003eMolecular Formula: C₁₅H₂₆N₄O₈\u003c\/li\u003e\n\u003cli\u003eMolecular Weight: 390.39 Da\u003c\/li\u003e\n\u003cli\u003eForm: Lyophilized white crystalline powder\u003c\/li\u003e\n\u003cli\u003eHalf-life: ~30 minutes\u003c\/li\u003e\n\u003cli\u003eCore Feature: Ultrashort peptide capable of penetrating cell nuclei to modulate gene expression epigenetically; primary target: vascular endothelial tissue.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003e2. Mechanism of Action\u003c\/h3\u003e\n\u003col\u003e\n\u003cli\u003e\n\u003cstrong\u003eEndothelial Cell Protection\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003eInteracts with the promoter of the MKI67 (Ki-67) gene to regulate endothelial cell proliferation, reduce endothelial apoptosis, and maintain the integrity of blood vessel walls. Normalizes endothelin-1 levels to ease vasoconstriction stress.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAnti-Atherosclerotic Activity\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003eUpregulates SIRT1 expression; improves intercellular gap junction proteins (Cx37, Cx43). Supports lipid metabolism balance and reduces pathological vascular remodeling.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMicrocirculation Improvement\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003ePromotes balanced angiogenesis, enhances peripheral blood flow, and alleviates disorders of microvascular circulation.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eNeuroprotective Effects\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003eModulates neuronal markers (Nestin, GAP43). In preclinical aging \u0026amp; Alzheimer’s models, it supports neuroplasticity and protects cerebrovascular tissue.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGeroprotective Properties\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003eReduces age-related degenerative changes in arteries; often researched in combination with other organ-specific bioregulator peptides (Cardiogen, Cortagen).\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003ch3\u003e3. Main Research Applications\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003eVascular endothelial aging \u0026amp; endothelial dysfunction research\u003c\/li\u003e\n\u003cli\u003eAtherosclerosis, peripheral circulatory impairment experimental models\u003c\/li\u003e\n\u003cli\u003eHypertension, hyperlipidemia \u0026amp; cardiovascular aging studies\u003c\/li\u003e\n\u003cli\u003eCerebrovascular health and neurodegeneration preclinical research\u003c\/li\u003e\n\u003cli\u003eMicrocirculation disturbance \u0026amp; tissue perfusion experiments\u003c\/li\u003e\n\u003cli\u003eCombined bioregulator therapy research (Vesugen + Cardiogen)\u003c\/li\u003e\n\u003cli\u003ePeptide epigenetic regulation \u0026amp; short peptide bioregulator pharmacology\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003e4. Reconstitution Instructions (Lyophilized Vial)\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eCommon specification: \u003c\/span\u003e\u003cstrong\u003e15mg \/ 20mg per vial\u003c\/strong\u003e\u003cspan\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003col\u003e\n\u003cli\u003eAllow vial to reach room temperature; disinfect rubber stopper with alcohol.\u003c\/li\u003e\n\u003cli\u003eSlowly inject Bacteriostatic Water along the inner glass wall. Avoid direct impact onto lyophilized powder.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cdiv\u003eReference mixing scheme: 15mg powder + 1.5mL BAC water → Concentration = 10 mg\/mL\u003c\/div\u003e\n\u003col start=\"3\"\u003e\n\u003cli\u003eGently rotate the vial to dissolve powder.\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003eDO NOT shake violently to prevent peptide degradation.\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003eQualified solution is clear and colourless.\u003c\/li\u003e\n\u003cli\u003eStorage Requirements\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cul\u003e\n\u003cli\u003eUnreconstituted lyophilized powder: Hermetically sealed, stored at -20°C, protected from light. Stable for up to 24 months.\u003c\/li\u003e\n\u003cli\u003eReconstituted peptide solution: Refrigerate 2°C ~ 8°C, stable within 28 days.\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003eDo not freeze reconstituted liquid.\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003e5. Research Administration Protocols\u003c\/h3\u003e\n\u003ch3\u003ePrimary Route: Subcutaneous Injection\u003c\/h3\u003e\n\u003ch3\u003eReference Experimental Dosage (Preclinical Research Reference)\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003eLow tolerance dose:\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003e100–150 mcg once daily\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eStandard experimental dose:\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003e200–300 mcg once daily\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eHigher experimental dose: Up to 1 mg once daily (limited long-term safety data)\u003c\/li\u003e\n\u003cli\u003eInjection site: Lower abdomen, anterior thigh; rotate injection positions regularly.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eReference Experimental Cycle (Khavinson pulsed bioregulator protocol)\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eContinuous administration for \u003c\/span\u003e\u003cstrong\u003e10–14 consecutive days as one course\u003c\/strong\u003e\u003cspan\u003e. Minimum 6–8 weeks washout interval before starting a new experimental course.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e6. Precautions \u0026amp; Observed Adverse Reactions\u003c\/h3\u003e\n\u003col\u003e\n\u003cli\u003ePure laboratory research compound. Not authorized for human therapeutic use.\u003c\/li\u003e\n\u003cli\u003eStrict aseptic technique required during reconstitution to prevent microbial contamination.\u003c\/li\u003e\n\u003cli\u003eDiscard solution immediately if turbidity, precipitation or discoloration appears.\u003c\/li\u003e\n\u003cli\u003eMinimal reported adverse effects in standard research dosages; occasional mild transient redness at injection site.\u003c\/li\u003e\n\u003cli\u003eLimited independent long-term high-dose safety data. Avoid uninterrupted administration beyond 14 days without washout.\u003c\/li\u003e\n\u003cli\u003eFor vascular research, Vesugen is frequently combined with Cardiogen for synergistic cardiovascular study models.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003chr\u003e\n\u003ch3\u003eShort Version (For Product Page \/ Customer Direct Message)\u003c\/h3\u003e\n\u003ch3\u003eVesugen (KED, Lys-Glu-Asp)\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eVesugen is a synthetic tripeptide bioregulator from the Khavinson peptide series. It targets vascular endothelial cells via epigenetic gene modulation, supporting blood vessel wall integrity, improving microcirculation and exerting vasoprotective and neuroprotective effects. Widely used in laboratory research on vascular aging, atherosclerosis, circulatory disorders and cerebrovascular health.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003eReconstitution\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eMix lyophilized powder with bacteriostatic water. Rotate gently; avoid violent shaking. Reconstituted solution must be refrigerated and used within 28 days.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003eReference Subcutaneous Research Dosage\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003e100–300 mcg once daily, administered in 10–14 day pulsed experimental courses.\u003c\/span\u003e\u003c\/p\u003e","brand":"我的商店","offers":[{"title":"10mg*10vials","offer_id":53703726596396,"sku":null,"price":46.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0979\/1406\/1100\/files\/256b15aa6e36f14e014d00fe4f0348fa05e823ef02f7512fb5774f7baf2a6127.png?v=1786601537","url":"https:\/\/0rw2.com\/products\/vesugen","provider":"0rw2.com","version":"1.0","type":"link"}